These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 15261707)
1. Predictors of improved mood over time in clinical trials for major depression. Marie-Mitchell A; Leuchter AF; Chou CP; James Gauderman W; Azen SP Psychiatry Res; 2004 Jun; 127(1-2):73-84. PubMed ID: 15261707 [TBL] [Abstract][Full Text] [Related]
2. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Hunter AM; Leuchter AF; Morgan ML; Cook IA Am J Psychiatry; 2006 Aug; 163(8):1426-32. PubMed ID: 16877657 [TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Schatzberg A; Roose S Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Silverstone PH; Salinas E J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362 [TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. Sheehan DV; Nemeroff CB; Thase ME; Entsuah R; Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088 [TBL] [Abstract][Full Text] [Related]
6. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
7. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression. Hunter AM; Ravikumar S; Cook IA; Leuchter AF Acta Psychiatr Scand; 2009 Apr; 119(4):266-73. PubMed ID: 19077131 [TBL] [Abstract][Full Text] [Related]
8. Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study. Zhou J; Wang X; Feng L; Xiao L; Yang R; Zhu X; Shi H; Hu Y; Chen R; Boyce P; Wang G BMC Psychiatry; 2021 May; 21(1):260. PubMed ID: 34011310 [TBL] [Abstract][Full Text] [Related]
9. Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. Lin CH; Lin KS; Lin CY; Chen MC; Lane HY J Clin Psychiatry; 2008 Jan; 69(1):54-9. PubMed ID: 18312038 [TBL] [Abstract][Full Text] [Related]
10. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Entsuah AR; Huang H; Thase ME J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046 [TBL] [Abstract][Full Text] [Related]
11. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853 [TBL] [Abstract][Full Text] [Related]
13. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Gibbons RD; Brown CH; Hur K; Davis J; Mann JJ Arch Gen Psychiatry; 2012 Jun; 69(6):580-7. PubMed ID: 22309973 [TBL] [Abstract][Full Text] [Related]
14. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)]. Hjalmarsson L; Corcos M; Jeammet P Encephale; 2005; 31(3):309-16. PubMed ID: 16142045 [TBL] [Abstract][Full Text] [Related]
15. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Bares M; Brunovsky M; Kopecek M; Novak T; Stopkova P; Kozeny J; Sos P; Krajca V; Höschl C Eur Psychiatry; 2008 Aug; 23(5):350-5. PubMed ID: 18450430 [TBL] [Abstract][Full Text] [Related]
16. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. Nelson JC; Mankoski R; Baker RA; Carlson BX; Eudicone JM; Pikalov A; Tran QV; Berman RM J Affect Disord; 2010 Jan; 120(1-3):133-40. PubMed ID: 19656577 [TBL] [Abstract][Full Text] [Related]
17. Changes in brain function of depressed subjects during treatment with placebo. Leuchter AF; Cook IA; Witte EA; Morgan M; Abrams M Am J Psychiatry; 2002 Jan; 159(1):122-9. PubMed ID: 11772700 [TBL] [Abstract][Full Text] [Related]
18. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091 [TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Costa e Silva J J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263 [TBL] [Abstract][Full Text] [Related]
20. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]